Novartis And Ionis' Heart Drug Fails In Trial, Triggering Biopharma Selloff
Story updated Rewritten when the story materially grows; the wire is checked every 15 minutesAbout this data
Novartis and Ionis' drug designed to lower Lp(a) failed to reduce cardiovascular risk in a key trial, leading to a significant selloff in biotech stocks. The failure has raised concerns about the efficacy of emerging heart medications and has cast doubt on similar drugs from competitors like Amgen and Lilly.
The trial results, which did not show a reduction in heart attack, stroke, or other major cardiovascular events, have reverberated through the biopharma sector, prompting a widespread drop in stock prices across the industry. This setback marks a notable failure for Novartis, which had high hopes for the drug's potential impact on cardiovascular health.
Sources
Every quote below is verbatim from the article it is attributed to.
“Novartis and Ionis' high-profile Lp(a) flop on Friday reverberated through biotech stocks on Tuesday, leading to a widespread drop.”
IBD — How Novartis And Ionis' High-Profile Failure Reverberated Through Biopharma“Along with several other drugmakers, Novartis has bet that lowering Lp(a) will cut the risk of sometimes fatal cardiovascular events.”
MarketWatch — Novartis's failed trial for cholesterol drug leads to broad biopharma selloff“<figure><div><img”
biopharma dive — Novartis, Ionis drug failure spurs questions about an emerging class of heart medicines“Novartis’ Ionis-partnered drug designed to lower levels of Lp(a), a known cardiovascular risk factor, failed to reduce patients’ risk of a heart attack, stroke, or other major cardiovascular event in the first late-stage test for a drug meant to tackle the mysterious molecule.”
fierce biotech — <a href="/biotech/novartis-lpa-drug-fails-lower-cardiovascular-risk-closely-watched-ph-3-trial" hreflang="en">Novartis Lp(a) drug fails to lower cardiovascular risk in closely watched ph. 3 trial</a>
“Novartis heart drug's trial failure cast doubt on Amgen and Lilly's cholesterol race”
quartz — Novartis heart drug's trial failure cast doubt on Amgen and Lilly's cholesterol race“A Novartis drug for a rare neuromuscular condition failed in a key study, the company's second major trial collapse in a matter of days.”
stat news — STAT+: Neuromuscular drug from Novartis fails in key study, adding to pressure on company
Earlier versions
- Sep 5, 5:30 AM — Novartis Drug Fails Key Test of New Approach to Heart Disease (3/3)
- Sep 8, 11:30 AM — Novartis Drug Pelacarsen Fails Key Test in Heart Disease Trial (7/5)
- Sep 8, 1:30 PM — Novartis Faces Third Drug Trial Failure in a Week (4/4)